Cohort study of patients with blood cancers in Languedoc-Roussillon

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects clinical and laboratory data from patients diagnosed with hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma. It aims to better understand the characteristics and progression of these conditions by following a cohort of patients over time. Participants must be adults with either a suspected or recently diagnosed blood cancer, and they will provide informed consent to be part of the study. The data gathered will help inform future treatment approaches and improve patient care.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Age over 18
* Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
* Having signed an informed consent
* Affiliated with a social security scheme

Exclusion criteria:

* Minor or major protected
* Patients who have received treatment for hematological pathology

Where it's running

• Hematology department - UHMontpellier Saint éloi
  Montpellier, France Recruiting

Study contacts

• Principal investigator: Guillaume Cartron — University Hospital, Montpellier
• Study coordinator: Valerie ROUILLE
• Email: v-rouille@chu-montpellier.fr

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• CD45RA-depleted donor cells to help fight stubborn viral infections after haploidentical transplant

  This trial tests whether giving patients specially prepared donor immune cells (CD45RA-depleted DLI) can help clear viral infections that linger after a stem cell transplant and who have not fully recovered their immunity.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai, SH · NCT07662369

• Identifying biomarkers for CAR-T cell therapy in cancer patients

  This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.

  Recruiting University Hospital, Lille · Lille and 1 other locations · NCT07609485

• QH101 Vδ2 T-cell therapy for adults with relapsed or advanced malignant tumors

  This study will try QH101, an off-the-shelf Vδ2 T-cell therapy, in adults with relapsed or advanced blood cancers or solid tumors to see if it is safe and helps fight tumors.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07570563

• Short versus long maribavir treatment after allogeneic stem cell transplant

  This trial tests whether a shorter or longer course of maribavir helps adults with refractory CMV infection after their first allogeneic stem cell transplant.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07511127

• Seeing if DCog Short on an iPad can spot neurotoxicity in CAR-T patients

  This study tests whether a self-report iPad tool called DCog Short can help identify neurotoxicity in people receiving CAR-T cell therapy.

  Recruiting Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07403812

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.